NCT00369473View on ClinicalTrials.gov

Long-Term Assessment of Safety and Physical Function With AMG 108 in RA

PHASE2CompletedINTERVENTIONAL

Enrollment

690

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Rheumatoid Arthritis

Interventions

DRUG

AMG 108

125 mg via SC (subcutaneous) injection every 4 weeks

DRUG

AMG 108

250 mg via SC (subcutaneous) injection every 4 weeks

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY